Kai Ming Medical -B (stock code: 2500) announced that Mr. Wang Fei has officially appointed Chief Financial Officer of the Company with effect from 4 January 2024. Mr. Wang has more than 20 years of financial and strategic planning experience and has held senior finance positions at Sanseng Pharmaceuticals Group and Aslikon. This appointment is a decision taken after Mr. Gima Hai Yue resigned on June 2, 2023, after a period of vacancy and a recommendation process by the Nomination Committee of the Board of Directors. At the same time, Kai Ming Medical-B shares have been suspended from trading on the exchange from 23 November 2023 and will continue to be suspended until further notice. Shareholders and potential investors should act with caution.

Kai Ming Medical -B (stock code: 2500) announced that Mr. Wang Fei has officially appointed Chief Financial Officer of the Company with effect from 4 January 2024. Mr. Wang has more than 20 years of financial and strategic planning experience and has held senior finance positions at Sanseng Pharmaceuticals Group and Aslikon. This appointment is a decision taken after Mr. Gima Hai Yue resigned on June 2, 2023, after a period of vacancy and a recommendation process by the Nomination Committee of the Board of Directors. At the same time, Kai Ming Medical-B shares have been suspended from trading on the exchange from 23 November 2023 and will continue to be suspended until further notice. Shareholders and potential investors should act with caution.